Max Bayer is a Staff Writer for Biotech, with his work also appearing in Fierce Pharma. Max specializes in covering the biotechnology industry, with a focus on pipeline developments, drug advancements, investment trends, and executive appointments. His articles provide in-depth analysis and insights into the rapidly evolving world of biotech.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Max Bayer's coverage primarily focuses on the healthcare and pharmaceutical industry, specifically on biotech, drug development, FDA approvals, and clinical trials. His articles often contain press releases and cite data from private sector announcements.
To effectively reach out to Max Bayer, consider providing pitches related to groundbreaking advancements in biotechnology or pharmaceuticals with a focus on new drug applications, significant leadership changes within prominent companies in the industry, as well as noteworthy partnerships or deals between key players. Additionally, offering insights supported by reliable data could enhance the appeal of your pitch.
Given that Max Bayer does not have a specific geographic focus mentioned but covers global developments within the healthcare and pharmaceutical sectors, ensure that your pitches reflect international relevance rather than being region-specific.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The US government is paying Siga $113 million to stockpile additional courses of the smallpox and mpox treatment known as Tpoxx. The project falls under …
By: Max Bayer
The deluge of legal action against pharmacy benefit managers continued Wednesday, with Vermont Attorney General Charity Clark filing a lawsuit claiming …
By: Max Bayer
Fresh off Eli Lilly's tirzepatide approval for weight loss in China , Beijing-based Gan & Lee Pharmaceuticals posted Phase 2b data of its …
By: Max Bayer
Merck's monoclonal antibody to protect infants from RSV hit its goals in a Phase 2b/3 trial, putting the US drugmaker a step closer to competing …
By: Max Bayer
Dren Bio inked a research pact with Novartis for select myeloid engagers to treat cancer, marking its second collaboration with a large pharma.
By: Max Bayer
The US Treasury has committed $667 million for a global Pandemic Fund hosted by the World Bank, a third of the $2 billion the fund …
By: Max Bayer
The FDA has expanded the approval of BioMarin's treatment for a genetic neurological condition that spurs seizures and twitching in young children.
By: Max Bayer
Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies. The French pharma deprioritized a Phase 2 drug …
By: Max Bayer
European regulators are poised to approve Novo Nordisk's blockbuster drug Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese …
By: Zachary Brennan, Max Bayer
Pharma has a message to investors about the results of the first round of drug price negotiations under the Inflation Reduction Act: It's fine. …
(833) 317-6278 
